ADC Therapeutics SA Common Shares
IPOADC Therapeutics | Innovating Science. Inspiring Hope.
ADC Therapeutics SA Common Shares is a biotech company in Lausanne, Switzerland, founded in 2011. It has raised $501.0M across 6 rounds, most recently a $276.0M Series E in June 2019.
- Headquarters
- Lausanne
- Employees
- 201–500
- Founded
- 2011
- Business Model
- B2B
- Website
- adctherapeutics.com
- Total Funding
- $501.0M
- Last Round
- $276.0M Series EJun 2019
- Rounds
- 6
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 6 funding rounds and 4 investors for this company. to use credits for reveals, or explore the API.
About
ADC Therapeutics is a commercial-stage oncology company pioneering targeted antibody drug conjugate (ADC) therapies, with its FDA-approved ZYNLONTA (loncastuximab tesirine-lpyl) for relapsed or refractory large B-cell lymphoma. The company is advancing its ADC portfolio into earlier lines of hematologic cancers and solid tumors to address significant unmet medical needs.
Funding & Exit History
May 2020
Investors
Tech & App Stack
Companies in related industries
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...

Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/adc-therapeutics-sa-common-shares"><img src="https://indexed.vc/api/badge/company/adc-therapeutics-sa-common-shares" alt="ADC Therapeutics SA Common Shares on Indexed.vc" width="260" height="76" /></a>
